The key to slowing cognitive decline is diagnosing the disease as early as possible. And that’s exactly what Johnson & Johnson scientists are relentlessly pursuing.

Imagine reversing the course of conditions like Alzheimer’s or multiple sclerosis, in which cells of the central nervous system stop working or die. Researchers at Johnson & Johnson are hot on the trail of innovative solutions that may do just that, preventing often-debilitating symptoms along the way.

Injections that allow people with schizophrenia to go longer between treatments. Digital tools that may lead to the creation of more effective medications. Programs that ensure mental illness is properly diagnosed. These are just a few of the ways Johnson & Johnson is addressing the largest unmet need in healthcare.

With COVID-19 dominating the news this year, chances are you’ve also read about clinical studies that are underway for investigational vaccines. For a glimpse at what the experience of participating in a clinical study is like, we spoke to people across the country who took part in a clinical trial.

Johnson & Johnson and the National Academy of Medicine have collaborated on a competition to kick-start research that’s poised to revolutionize the field of healthy longevity. Meet some of the researchers who have big ideas in the pursuit of “immorbidity.”

It’s the sixth leading cause of death in the United States, with no existing cure. But these researchers are committed to finding better ways to diagnose, treat and prevent the debilitating disease, using everything from innovative biomarker tracking to a potential vaccine for early stage patients.

Cancer. Alzheimer’s. Even suicide risk. The clues to preventing these and other conditions could be found in our DNA—and these scientists are at the forefront of promising new genetic data research to uncover them.

Johnson & Johnson aspires to change the trajectory of health for humanity. And Tom Heyman helps make that lofty goal a reality through his work as the head of Johnson & Johnson’s venture capital division, which invests in dozens of companies each year. He shares what’s on his radar for 2019.

With company leaders at the World Economic Forum in Davos this week, Johnson & Johnson’s Chief Scientific Officer weighs in on the next great global healthcare challenge—and how we can all come together to help address it.

From the incredible researchers who’ve dedicated their life’s work to fighting chronic diseases to those who work tirelessly to bring hope to underserved populations, we’re taking a moment to celebrate the company’s many heroes.